Optimal working dilution should be determined by the investigator.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Konzentration
0.5 mg/mL
Buffer
PBS, 0.09 % NaN3, 1 % BSA
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C
Informationen zur Lagerung
Store at 2-8 °C.
Target
CD300a (CD300A)
Andere Bezeichnung
CD300A / CMRF35H
Hintergrund
Immune responses are regulated by opposing positive and negative signals triggered by the interaction of activating and inhibitory cell surface receptors with their ligands. Shibuya et al. identified novel paired activated and inhibitory immunoglobulin-like receptors, designated myeloid-associated immunoglobulin-like receptor (MAIR) I and MAIR-II, whose extracellular domains are highly conserved by each other. MAIR-I, expressed on the majority of myeloid cells, including macrophages, granulocytes, mast cells, and dendritic cells, contains the tyrosine-based sorting motif and the immunoreceptor tyrosine-based inhibitory motif-like sequences in the cytoplasmic domains. On the other hand, MAIR-II, expressed on subsets of peritoneal macrophages and B cells, associates with the immunoreceptor tyrosine-based activation motif-bearing adaptor DAP12. MAIR-I is also known as CD300a/ CMRF-35-like Ig-like molecule-8 (CLM-8)/leukocyte mono-Ig-like receptor 1 (LMIR1). MAIR-II is also known as CD300d/LMIR2/CLM-4/dendritic cell-derived Ig-like receptor 1 (DIgR1).Synonyms: CD300 antigen-like family member A, CLM-8, CMRF-35-H9, CMRF35-H, CMRF35-H9, CMRF35-like molecule 8, IRC1/IRC2, IRp60, Inhibitory receptor protein 60, NK inhibitory receptor